GSK Severe Asthma Drug Nucala OK'd
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline PLC on Nov. 4 gained the FDA's blessing to market Nucala (mepolizumab) as the first anti-interleukin-5 treatment in the US for adults and adolescents with severe asthma with an eosinophilic phenotype – gaining broader use than a panel of experts had advised.